EP06.02-05 Agreement among Programmed Cell Death Ligand-1 Immunohistochemistry Results Using 73-10, 22C3 and 28-8 Antibodies for Lung Cancer

T. Saito,M. Ishida, Y. Takeyasu,T. Utsumi,N. Maru,H. Matsui,Y. Taniguchi,H. Hino,T. Kurata, T. Murakawa

Journal of Thoracic Oncology（2023）

引用 0|浏览2

暂无评分

摘要

Our previous report indicated that the results of Dako 28-8 could be translated into those of 22C3 but not vice versa (Saito T et al, Lung Cancer 2018). This study aimed to investigate agreement among three PD-L1 immunohistochemistry assays (Dako 73-10, 22C3 and 28-8) for non-small cell lung cancer (NSCLC).

查看译文

关键词

lung cancer,immunohistochemistry,antibodies

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要